Genomic studies have revealed significant branching heterogeneity in cancer. Studies of resistance to tyrosine kinase inhibitor therapy have not fully reflected this heterogeneity because resistance in individual patients has been ascribed to largely mutually exclusive on-target or off-target mechanisms in which tumors either retain dependency on the target oncogene or subvert it through a parallel pathway. Using targeted sequencing from single cells and colonies from patient samples, we demonstrate tremendous clonal diversity in the majority of acute myeloid leukemia (AML) patients with activating internal tandem duplication mutations at the time of acquired resistance to the FLT3 inhibitor quizartinib. These findings establish that clinical resistance to quizartinib is highly complex and reflects the underlying clonal heterogeneity of AML.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501146 | PMC |
| http://dx.doi.org/10.1182/blood-2016-04-711820 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances and Challenges in Quizartinib-Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies.
Eur J Haematol
January 2025
Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
FLT3 mutations are among the most common genetic alterations in acute myeloid leukemia (AML) and are associated with poor prognosis. Significant advancements have been made in developing FLT3 inhibitors (FLT3Is), such as quizartinib, which have improved treatment outcomes in both newly diagnosed and relapsed/refractory AML. Resistance to FLT3Is remains a major clinical challenge, driven by diverse mechanisms including FLT3 point mutations, cellular escape pathways, and the influence of the bone marrow microenvironment.
View Article and Find Full Text PDFQuizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML.
J Hematol Oncol
November 2024
Georgia Cancer Center at Augusta University, 1410 Laney Walker Blvd., CN2222, Augusta, GA, 30912, USA.
Mutations in FMS-related receptor tyrosine kinase 3 (FLT3) are among the most common alterations in acute myeloid leukemia (AML), present in ≈30% of newly diagnosed AML cases. Internal tandem duplications (ITD) in FLT3 (FLT3-ITD) occur in ≈25% of newly diagnosed AML cases and are associated with unfavorable outcomes. Quizartinib (formerly AC220) is a novel, second-generation, highly potent, and selective type II FLT3 inhibitor.
View Article and Find Full Text PDFMyeloid malignancies carrying somatic DNMT3A mutations (DNMT3Amut) are usually resistant to standard therapy. DNMT3Amut leukemia cells accumulate toxic DNA double strand breaks (DSBs) and collapsed replication forks, rendering them dependent on DNA damage response (DDR). DNA polymerase theta (Polθ), a key element in Polθ-mediated DNA end-joining (TMEJ), is essential for survival and proliferation of DNMT3Amut leukemia cells.
View Article and Find Full Text PDFAutophagy and inflammasome activation are associated with poor response to FLT3 inhibitors in patients with FLT3-ITD acute myeloid leukemia.
Sci Rep
October 2024
Department of Medical Images, Hematology, and Oncology, Ribeirão Preto Medical School, University of São Paulo, 3900 Bandeirantes Avenue, Ribeirão Preto, São Paulo, 14040-900, Brazil.
Article Synopsis
- Acute myeloid leukemia (AML) is a complex disease with diverse clinical features and significant molecular challenges, particularly related to FLT3 mutations.
- Researchers investigated the interactions between autophagy and the inflammasome to understand how these pathways might impact FLT3 inhibitor effectiveness in treating AML.
- Their findings suggest that autophagy and inflammasome activation are linked to poor responses to FLT3 inhibitors, indicating a need for further study on these pathways to enhance treatment strategies.
[Pathogenesis and treatment of acute myeloid leukemia with FLT3 mutations].
Rinsho Ketsueki
October 2024
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine.
Article Synopsis
- FLT3 mutations are the most common genetic changes found in adult acute myeloid leukemia (AML), affecting about 30% of patients and linked to a poor prognosis, especially the FLT3-ITD variant.
- Allogeneic hematopoietic cell transplantation is recommended for younger patients in their first remission, and recent clinical use of FLT3 inhibitors like gilteritinib and quizartinib has shown promise in improving patient outcomes.
- New treatment strategies are being developed, including combination therapies and maintenance treatments, while challenges like treatment resistance due to additional mutations remain a concern.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!